Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Wanbury Ltd. Share Price
Day's Range
Low
₹188.20
High
₹194.80
Price Summary
| Previous Close | ₹190.52 |
|---|---|
| Day's Range | ₹188.20 - ₹194.80 |
| Open | ₹190.88 |
| 52 Week Range | ₹161.50 - ₹358.85 |
| Volume | 1,04,828 |
| Market Cap | ₹0.00 |
| Previous Close | ₹190.15 |
|---|---|
| Day's Range | ₹188.00 - ₹197.90 |
| Open | ₹197.90 |
| 52 Week Range | ₹162.00 - ₹360.00 |
| Volume | 11,299 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 200.06 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 15.47 |
| TTM EPS (₹) | 12.29 |
| P/E Ratio | 25.19 |
| Book Value(₹) | 9.91 |
| PAT Margin (%) | 5.06 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 35.97 |
| Trade Value ( ₹ in Lacs) | 21.64 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 15.47 |
| TTM EPS (₹) | 12.29 |
| P/E Ratio | 25.19 |
| Book Value(₹) | 9.91 |
| PAT Margin (%) | 5.06 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 35.97 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1631.84 | 5995.14 |
| Expenses | N/A | N/A |
| PBT | 136.06 | 295.51 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 134.9 | 305.3 |
About Wanbury Ltd.
| Founded | 1988 |
|---|---|
| NSE Symbol | WANBURY |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,24,202.42 | 1,768.00 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,64,141.24 | 9,950.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,74,402.47 | 4,585.10 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,26,811.28 | 2,347.00 | 917.95 - 917.95 |
| Zydus Lifesciences Ltd. | 1,23,685.49 | 1,239.95 | 835.50 - 835.50 |
| Apollo Hospitals Enterprise Ltd. | 1,21,066.68 | 8,420.00 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,15,707.34 | 671.20 | 0.00 - 0.00 |
| Dr. Reddy's Laboratories Ltd. | 1,11,868.03 | 1,340.25 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,11,650.13 | 1,382.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,02,195.62 | 2,475.95 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
AstraZeneca Pharma India informs about updates
GPT Healthcare informs about earnings call
In compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, GPT Healthcare has informed an Earnings Call is scheduled on Friday, November 6, 2026 at 11.00 A.M (IST) to discuss the financial performance of the Company on the Un-Audited Financial Results for the for the 2nd quarter and half year ended September 30, 2026. In this regard, the company has enclosed conference call details with this letter.
The above information is a part of company’s filings submitted to BSE.
Divi's Laboratories informs about earnings call
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Divi's Laboratories has informed that it enclosed the schedule of earnings conference call for the quarter and half year ended September 30, 2026, to be held on November 07, 2026.
The above information is a part of company’s filings submitted to BSE.
IOL Chemicals and Pharmaceuticals submits investor presentation
IOL Chemicals and Pharmaceuticals submits newspaper publication
Pursuant to the Regulation 47 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, IOL Chemicals and Pharmaceuticals has informed that it enclosed copies of the newspaper publication of un-audited Financial Results for the quarter and half year ended 30th September 2026 published in Business Standard, Economic Times, Financial Express, and Punjabi Jagran on 31st October 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Wanbury Ltd. is ₹190.52 as of 2026-11-02.
The market capitalisation of Wanbury Ltd. is ₹664.90 as of 2026-11-02.
The 1-year return of Wanbury Ltd. is -72.33% as of 2026-11-02.
The P/E ratio of Wanbury Ltd. is 11.76 as of 2026-11-03.
The 52-week high and low of Wanbury Ltd. are ₹358.85 and ₹161.50, respectively, as of 2026-11-02.
People Also Ask
Wanbury Ltd. was originally incorporated as Pearl Organics Limited in August 1988. The company adopted the name Wanbury Limited in September 2004. This change reflected its transition into a pharmaceutical manufacturing business with a broader operational scope and growing presence in domestic and international markets.
Wanbury Ltd. is a publicly listed company whose equity shares are traded on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Being listed on these exchanges allows participation from both retail and institutional investors and ensures compliance with regulatory disclosure and governance standards.
Wanbury Ltd. generates revenue through the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and pharmaceutical formulations. The company produces and exports medicines used in therapeutic areas such as diabetes management. Its operations include production, research, and distribution across multiple regulated and semi-regulated global markets.
Pradeep Patni serves as the Chief Executive Officer of Wanbury Ltd., having assumed the role in August 2024. He is responsible for overseeing the company’s strategic direction and operations, working alongside Mohan Kumar Rayana, who is the Promoter and Whole-Time Director involved in leadership and governance functions.
Wanbury Ltd. is a pharmaceutical company engaged in the development and manufacturing of APIs and formulations. With over three decades of experience, it operates integrated facilities that support research and production. The company supplies its products to domestic and international markets, including regulated regions across various therapeutic categories.
Explore More Articles About Indices
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
